Ask AI
ProCE Banner Activity

Beamion LUNG-1: Patient-Reported Outcomes With Zongertinib for Previously Treated Advanced HER2-Mutant NSCLC

Conference Coverage
Slideset

Patient-reported outcomes in Beamion LUNG-1 show that pretreated patients with advanced HER2-mutant NSCLC experience improvement in disease-related symptoms and physical functioning with zongertinib.

Released: June 05, 2025

Expiration: December 04, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar